1. Introduction

ijms

International Journal of Molecular Sciences

Int. J. Mol. Sci.

1422-0067

Molecular Diversity Preservation International (MDPI)

10.3390/ijms130810461

ijms-13-10461

Review

Transforming Growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): A Matrix Protein with Dual Functions in Ovarian Cancer

Ween

Miranda P.

12 Oehler

Martin K.

13 Ricciardelli

Carmela

1 Discipline of Obstetrics and Gynaecology, School of Paediatrics and Reproductive Health, Research Centre for Reproductive Health, Robinson Institute, University of Adelaide, Adelaide, South Australia, 5000, Australia; E-Mails: miranda.ween@adelaide.edu.au (M.P.W.); martin.oehler@adelaide.edu.au (M.K.O.) 2 Research Centre for Infectious Diseases, School of Molecular Biosciences, University of Adelaide, South Australia 5005, Australia 3 Department of Gynaecological Oncology, Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia

* Author to whom correspondence should be addressed; E-Mail: carmela.ricciardelli@adelaide.edu.au; Tel.: +61-8-8313-8255; Fax: +61-8-8313-4099.

2012

21 08 2012

13 8 10461 10477 03 08 2012 16 08 2012

2012

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

Transforming growth factor-beta-induced protein (TGFBI, also known as βig-H3 and keratoepithelin) is an extracellular matrix protein that plays a role in a wide range of physiological and pathological conditions including diabetes, corneal dystrophy and tumorigenesis. Many reports indicate that βig-H3 functions as a tumor suppressor. Loss of βig-H3 expression has been described in several cancers including ovarian cancer and promoter hypermethylation has been identified as an important mechanism for the silencing of the TGFBI gene. Our recent findings that βig-H3 is down-regulated in ovarian cancer and that high concentrations of βig-H3 can induce ovarian cancer cell death support a tumor suppressor role. However, there is also convincing data in the literature reporting a tumor-promoting role for βig-H3. We have shown βig-H3 to be abundantly expressed by peritoneal cells and increase the metastatic potential of ovarian cancer cells by promoting cell motility, invasion, and adhesion to peritoneal cells. Our findings suggest that βig-H3 has dual functions and can act both as a tumor suppressor or tumor promoter depending on the tumor microenvironment. This article reviews the current understanding of βig-H3 function in cancer cells with particular focus on ovarian cancer.

ovarian cancer extracellular matrix TGFBI tumor suppressor invasion adhesion metastasis

1. Introduction

βig-H3 (also known as TGFBI for protein and TGFBI for gene) is a transforming growth factor beta (TGFβ) inducible secreted extracellular matrix (ECM) protein. The name βig-H3 was derived from its cloning as a major TGFβ responsive gene in lung adenocarcinoma cell line A549: TGFβ induced gene human clone 3 [1]. In the literature it has also been referred to as keratoepithelin [2], collagen fibre associated protein (RGD-CAP) [3], P78/70 [4], Big-h3 [5], β-igH3 [6], and β-ig [7]. βig-H3 is comprised of 683 amino acids and its secreted form has a predicted molecular mass of 68 kDa. Two isoforms of βig-H3 at 78 and 68 kDa have been reported to date [8], both of which are encoded by a single gene, TGFBI [9]. βig-H3 contains an N-terminal secretory signal (1–24 amino acids), a cysteine rich domain, four internal repetitive fasciclin-1 domains (FAS1 1–4), integrin binding motifs in the C-terminus known as Arg-Gly-Asp (RGD), YH18, and EPDIM and an internal NKDIL motif [10,11] (Figure 1).

2. βig-H3 Regulation and Function

βig-H3 participates in many physiological processes including morphogenesis, adhesion/migration, angiogenesis, and inflammation [12]. It also has a role in reproduction [13,14] and wound healing [15,16]. A wide range of cells have been shown to induce expression of βig-H3 following treatment with TGFβ including, fibroblasts, chondrocytes, smooth muscle cells, corneal epithelial cells, and various types of cancer cells [12]. βig-H3 is regulated not only by TGFβ, but also by retinoid [17], IL-4 [15], IL-1 [18], and TNF-α [18] in various cell types. TNF-like ligand 1A can regulate the inflammatory processes in a human acute monocytic leukemia cell line (THP-1) through modulation of the βig-H3 expression via both protein kinase C and extracellular signal-regulated kinase pathways [19]. βig-H3 could also be induced in human mesenchymal stem cells by treatment with the phospholipid, lysophosphatidic acid that is enriched in the serum of cancer patients [20]. Recent evidence suggests that βig-H3 expression can also be regulated by the microRNA, miR-21 [5]. βig-H3 has been shown to trigger phosphorylation and to activate several intracellular pathways including AKT, extracellular signal-regulated kinase, focal adhesion kinase (FAK), and paxillin, thus mediating adhesion and migration of vascular smooth muscle cells through interactions with αvβ5 integrins [21].

Immunohistochemical studies show that βig-H3 is distributed in the ECM of a wide range of developing and mature tissues, including endothelial cells of human vascular tissues [22], papillary dermis [10], primary spongiosa, periosteum, and perichondrium [23]. It has also been associated with bone formation [24,25]. βig-H3 expression is induced in endothelium and stroma-derived cells in the healing cornea [7] and reactive astrocytes in rat cerebral cortex at wound sites [16].

In many cell types, βig-H3 functions as a linker protein which connects various matrix molecules to each other as well as facilitating cell-collagen interactions [4,26–28]. βig-H3 can bind to type I, II, and IV collagens as well as proteoglycans such as biglycan and decorin [28]. It has been shown that βig-H3 binds covalently to collagen VI microfibrils [27] and interacts with fibronectin [26] and various integrins [29], which are the only βig-H3 cell surface receptors identified to date (reviewed in [12]).

βig-H3 plays a role in the adhesion and migration of a wide range of cells including keratinocytes, fibroblasts, chondrocytes, osteoblasts, and endothelial cells (reviewed by [25]). Effects on adhesion are mediated through interactions with various integrins including α1β1, α3β1, αvβ3, and αvβ5 [10,30–33] via integrin binding motifs in the βig-H3 protein. These include the well characterized RGD motif in the C-terminus [34] as well as the NKDIL motif (amino acids 354–358) [11] and the EPDIM motif (amino acids 617–621) [11] in the second and fourth FAS-1 domains, respectively (Figure 1). The structural analysis of the NKDIL and EPDIM sequence motifs show that they can adopt a β-turn structure similar to the RGD motif to interact with integrins during adhesion [34]. Another adhesion motif shown to support αvβ5 integrin mediated adhesion of lung fibroblast MRC-5 cells [29], vascular smooth muscle cells [21], and endothelial cells [35], is the highly conserved tyrosine and histidine residues YH18 motif (amino acids 563–580) in the fourth FAS-1 domain, which is flanked by several leucine/isoleucine residues (Figure 1).

3. βig-H3 Roles in Disease 3.1. Role in Diabetes and Corneal Dystrophies

βig-H3 has been associated with a range of diseases including nephropathy [36], atherosclerosis [22], and rheumatoid arthritis [15,18], as well as corneal disorders. Its role in inflammatory disease processes is not well understood. βig-H3 expression is prominent in the kidney and increased in the urine of diabetics [37,38]. It has been suggested that combined monitoring of albumin excretion rate and urinary βig-H3 can predict the severity of diabetic nephropathy [39]. βig-H3 has been shown to induce pericyte apoptosis through its RGD motif, which may constitute an important pathogenic mechanism leading to pericyte loss in diabetes [40]. Recent studies also suggest that βig-H3 may be involved in kidney pathology associated with preeclampsia, and was detectable in the urine of these patients but not in non-preeclamptic pregnant women [41].

Mutations in the TGFBI gene are well characterized in a number of corneal dystrophies, which lead to the development of corneal deposits and impaired vision [42–45]. Corneal dystrophies represent the only known pathological disease associated with mutations in TGFBI. The mechanisms of pathogenesis are unknown but mutations in TGFBI may impair protein folding or βig-H3 secretion and result in the deposition and accumulation of mutant βig-H3 protein that has increased stability [46].

3.2. Roles in Cancer 3.2.1. Role as Tumor Suppressor

Many reports indicate βig-H3 is an inhibitor of tumorigenesis and suggest that βig-H3 functions as a tumor suppressor (summarized in Table 1). Furthermore, reduced expression of βig-H3 has been observed in many tumor types. Down-regulation of βig-H3 was found to correlate highly with promoter hypermethylation in lung, prostate, and breast cancer cells. Promoter hypermethylation is considered an important mechanism involved in the silencing of the TGFBI gene in human cancer cells [47].

βig-H3 overexpression has been shown to markedly reduce tumorigenicity of CHO cells and lung cancer cells in vivo [48,50]. βig-H3 expression is markedly suppressed in asbestos- and radiation-induced tumorigenic cells, whilst ectopic expression of βig-H3 significantly suppresses tumorigenicity and progression in human bronchial epithelial cells [50–52]. βig-H3 has also been reported to mediate apoptosis through the RGD motif in CHO cells [49] and the EPDIM motif in osteosarcoma cells [57]. A recent observation by Becker et al. suggested that increased expression of βig-H3 suppresses neuroblastoma cell adhesion to various ECM proteins, thus inhibiting their proliferation and invasion [2]. More recent studies demonstrating that the loss of βig-H3 predisposes mice to spontaneous tumor development have provided strong in vivo evidence that βig-H3 functions as a tumor suppressor [58]. Mouse embryonic fibroblasts isolated from TGFBI^−/− mice displayed increased frequencies of chromosomal aberration, abnormal mitoses, and enhanced proliferation [58]. The loss of chromosomal integrity may explain the increased tumor tendency in the TGFBI knockout mice.

Recent studies using lung and breast cancer cell lines have also shown that βig-H3 induced adhesion to ECM proteins, but reduced the motility and invasive ability of these cells both in vitro and in vivo [54]. These findings indicate that βig-H3 can restrain the metastatic potential of cancer cells and thus support the tumor suppressor function of βig-H3. Stable βig-H3 knockdown mutants established from a mesothelial cell line, Met-5A, exhibited an elevated proliferation rate, enhanced plating efficiency, increased anchorage-independent growth, and a more active PI3K/AKT/mTOR signaling pathway [55]. These findings suggest that βig-H3 may repress mesothelioma tumorigenesis and progression by inhibiting the PI3K/AKT signaling pathway.

3.2.2. Roles as Tumor Promoter

Although there is strong evidence that βig-H3 has a tumor suppressor function, there is also convincing data in the literature reporting a tumor-promoting role for βig-H3 (summarized in Table 2). High βig-H3 expression has been shown for various tumor tissues and cell lines [6,62–70] and in many cancers elevated expression also relates to more aggressive tumors [6,70,71]. Furthermore, several reports indicate that βig-H3 can mediate cancer cell invasion and metastasis as well as enhance cancer cell extravasation [71–74].

βig-H3 has been shown to mediate lymphatic endothelial migration and adhesion to ECM under low oxygen conditions [75]. These observations suggest that during hypoxia, which commonly occurs in tumors, βig-H3 may aid the metastatic process by promoting the adhesion to lymphatic endothelial cells. More recently βig-H3 has been shown to be highly expressed by mesenchymal stem cells derived from human adipose tissue and to stimulate proliferation and adhesion of the A459 human lung adenocarcinoma cell line [20]. Furthermore, βig-H3 observed at the invasion front of melanomas co-localized with fibrillar fibronectin/tenascin-C/periostin structures, suggesting an important role for βig-H3 in ECM deposition and invasive growth of melanoma cells [76]. siRNAs against βig-H3 transfected into human hepatocellular carcinoma cells showed that βig-H3 increases the invasive potential of those cells by regulating MMP-2 and -9 secretion [77]. Thus, due to its tumor promoting role βig-H3 is a promising therapeutic target.

3.2.3. Role of βig-H3 in Ovarian Cancer 3.2.3.1. Tumor Suppressive role of βig-H3 in Ovarian Cancer

One of the crucial steps in ovarian cancer metastasis involves the implantation of ovarian cancer cells onto the peritoneal lining. As the underlying molecular mechanisms have not been well characterized we have studied the interaction between ovarian cancer and peritoneal cells in vitro. The ECM protein βig-H3 was found to be differentially regulated in the secretome of peritoneal-ovarian cancer cell co-culture. We demonstrated that βig-H3 is abundantly expressed by peritoneal cells and can promote ovarian cancer cell motility, invasion, and adhesion to LP-9 peritoneal cells [61].

Our recent studies investigating the role of βig-H3 in ovarian tumorigenesis have demonstrated low expression of βig-H3 in ovarian cancer cell lines and ovarian cancer tissue [61]. This is consistent with other studies demonstrating a down-regulation of βig-H3 in cancer cells and more recent studies demonstrating that the TGFBI gene is frequently hypermethylated in ovarian tumors [59,60]. Our data, showing high levels of βig-H3 immunostaining in normal ovarian surface epithelial cells (Figure 2a) and benign serous ovarian tumors (Figure 2b) but low βig-H3 immunostaining in human serous ovarian cancer cells (Figure 2c), suggest that βig-H3 is down-regulated during the process of ovarian cancer tumorigenesis [61]. Our findings, that high concentrations (>5 μg/mL) of βig-H3 can induce ovarian cancer cell death, also support an anti-tumorigenic role for βig-H3 [61]. The use of TGFBI methylation as novel epigenetic biomarker for discriminating ovarian cancer from non-cancer or borderline tumors [59] should be further explored.

3.2.3.2. Pro-Tumorigenic Role of βig-H3 in Ovarian Cancer

In our recent study we have demonstrated that βig-H3 induces both motility and invasion of OVCAR-5 and SKOV-3 cells, but does not affect motility or invasion of OVCAR-3 ovarian cancer cells that are known to be less metastatic [61]. We have also shown that βig-H3 promotes attachment of OVCAR-5, SKOV-3, and OVCAR-3 to LP-9 peritoneal cells [61]. These findings suggest that βig-H3 may function in multiple ways to promote ovarian cancer metastasis and that the effects on motility may be independent of those on adhesion.

In our study, the effects of βig-H3 on OVCAR-5 cells were independent of the βig-H3 RGD integrin binding motif (amino acids 642–644), since treatment with ERGDEL peptide did not block the ability of βig-H3 to promote ovarian cancer cell motility, invasion, or adhesion to peritoneal cells. Our data suggests that βig-H3 activity on OVCAR-5 cells is mediated by other sites in the βig-H3 molecule other than the RGD motif, which may include the EPDIM and NKDIL motifs as well as the sequence spanning the YH18 motif.

3.2.3.3. βig-H3 Processing by Ovarian Cancer Peritoneal Interactions

We have shown that βig-H3 cleavage in the ovarian cancer-peritoneal cell co-culture occurs between amino acid residues 27–76 in the N-terminus and amino acid residues 626–657 in the C-terminal domain [61]. Although the functional role of the N-terminal βig-H3 domain has not been well studied, the C-terminus has several integrin binding motifs including the RGD, YH18, and EPDIM sequences. βig-H3 fragments including the EPDIM and the RGD motif, have recently been shown to promote apoptosis of osteosarcoma cells [57]. A truncated βig-H3 lacking the EPDIM but not the RGD motif failed to induce apoptosis in this cell type [57].

Whilst it is not known whether the C-terminal processed βig-H3 in the secretome of the ovarian cancer-peritoneal co-culture retains its RGD sequence at amino acid 642–644, the EPDIM motif at amino acid 617–621 is maintained in the C-terminal processed βig-H3. Crystal structure of the FAS-1 domains (Drosphilia TGFBI/βig-H3 homologue) has identified a novel fold domain consisting of a seven-stranded β-wedge and a number of α-helices in the 3rd and 4th FAS-1 domains [88]. The EPDIM motif maps to a conserved kink in the β6 strand of the fourth βig-H3 FAS-1 domain and is predicted to be buried within the domain protein core [88]. βig-H3 processing by proteases, including plasmin between amino acids 626–655 may expose the EPDIM motif (amino acids 617–621) site for integrin interactions and may promote the integrin binding activity on the surface of the peritoneum [89–91] with ovarian cancer cells [92,93] and increase ovarian cancer metastatic behavior.

Interestingly, βig-H3 processing was only observed when ovarian cancer cells and peritoneal cells were in direct physical contact in culture, or when the cells shared the same growth media in the co-culture system [61]. βig-H3 processing did not occur when conditioned media from peritoneal cells was added to cultured ovarian cancer cell lines, or when conditioned media from ovarian cancer cells was added to the cultured peritoneal cells. This indicates that βig-H3 processing is not mediated by a simple up-regulation of ovarian cancer cell derived proteases but requires multiple levels of cross-talk between both ovarian cancer and peritoneal cells. A similar paracrine effect was previously reported for endometrial cancer epithelium–stroma cell co-cultures, where hepatic growth factor secreted by the stromal cells acted on the endometrial cancer cells by inducing the cleavage of MMPs pro-forms to mature active forms [94]. Our findings suggest, however, that cleavage of βig-H3 in the ovarian cancer and peritoneal cell co-culture is not MMP mediated as the broad spectrum MMP inhibitor, GM6001, failed to inhibit βig-H3 processing. Instead, we found that the protease plasmin cleaved βig-H3 in the same region as observed in the ovarian cancer-peritoneal cell co-culture and that this could be inhibited by a cocktail of protease inhibitors, including serine protease inhibitors. We demonstrated that plasmin activity was increased in the conditioned medium of co-cultured OVCAR-5 and LP-9 cells, whilst no plasmin activity could be detected in the conditioned medium collected from those cells cultured alone [61]. These findings add to our understanding of the interaction between ovarian cancer and peritoneal cells and suggest that increased plasmin production and βig-H3 cleavage may be early events in the process of ovarian cancer metastasis.

3.2.3.4. βig-H3 as a Predictor of Therapy Response

The level of βig-H3 in ovarian cancer tissue has been shown to be a predictive marker of response to treatment with the aromatase inhibitor letrozole [95] and the chemotherapeutic drug paclitaxel [86]. The loss of βig-H3 induces a specific resistance to paclitaxel and is associated with mitotic spindle abnormalities in ovarian cancer cells [86]. Paclitaxel-resistant cells treated with recombinant βig-H3 protein show integrin-dependent restoration of paclitaxel sensitivity via FAK- and Rho-dependent stabilization of microtubules [86]. More recent studies have also shown that the suppression of β3 integrin and βig-H3 increase the resistance of SKOV3 to paclitaxel [87]. A strong association between elevated βig-H3 expression and the response to chemotherapy has also been identified in lung cancer patients [96]. Lung cancer cells over-expressing βig-H3 displayed increased sensitivity to etoposide, paclitaxel, cisplatin, and gemcitabine. βig-H3-mediated induction of apoptosis occurred through its binding to αvβ3 integrin by proteolytic fragments of βig-H3 and not full length protein [96]. Together these data show that βig-H3 is also a potential therapeutic to improve response to chemotherapy in ovarian cancer patients.

4. Conclusions

Studies over the last 5 years have increased our understanding of the role of βig-H3 in cancer. However, there is conflicting data in the literature reporting that βig-H3 can have a tumor suppressive as well as a tumor promoting role in different cancer cells. These opposing effects of βig-H3 have been identified in several different laboratories and are unlikely to be due to biased observations. βig-H3 expression and function in cancer cells appears to be cell type specific and is affected by βig-H3 concentration but also by processing events by protease enzymes which can liberate integrin binding sites. As truncated forms of βig-H3 have been well documented to have differing functions it is likely that alterations in βig-H3 processing in different cell types is an important factor contributing to the disparate findings in literature. Our findings highlight the need for amino acid sequencing to confirm the presence of full length or truncated forms of βig-H3 [61]. The findings that siRNA TGFBI knockdown increased melanoma cell growth and invasion in vitro but greatly impaired subcutaneous tumor growth in nude mice highlights the importance of the tumor microenvironment for βig-H3 function [76]. Whether βig-H3 functions as a tumor suppressor or tumor promotor may also be dependent on interactions between other ECM proteins and specific integrin receptors present in the tumor microenvironment.

Our research demonstrating that βig-H3 is down-regulated in ovarian cancer and promotes ovarian cancer cell death supports a tumor suppressor role. However βig-H3 is abundantly expressed by peritoneal cells and can promote metastatic behavior of ovarian cancer cells. Consequently, in ovarian cancer, βig-H3 may act as a “double-edged sword”. The loss of βig-H3 promotes ovarian tumorigenesis, microtubule and chromosome instability and a more chemoresistant phenotype, however in the peritoneal microenvironment; βig-H3 produced by the peritoneal cells aids the metastatic process. Our ovarian cancer studies to date indicate that βig-H3 is a potential therapeutic target to inhibit ovarian cancer metastasis to the peritoneum. Further studies investigating therapeutic strategies to block βig-H3 action in ovarian cancer are therefore warranted. βig-H3 derived peptides could be used to both block ovarian cancer metastasis and enhance chemotherapy response.

Acknowledgments

This work was supported by the Cancer Council of South Australia & South Australian Health and Medical Research Institute (Senior Cancer Fellowship to CR), and the Ovarian Cancer Research Foundation, Australia.

References 1

Skonier

Neubauer

Madisen

Bennett

Plowman

G.D.

Purchio

A.F.

cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta

DNA Cell Biol199211511522

10.1089/dna.1992.11.511

1388724

Becker

Erdlenbruch

Noskova

Schramm

Aumailley

Schorderet

D.F.

Schweigerer

Keratoepithelin suppresses the progression of experimental human neuroblastomas

Cancer Res20066653145321

10.1158/0008-5472.CAN-05-3049

16707457

Hashimoto

Noshiro

Ohno

Kawamoto

Satakeda

Akagawa

Nakashima

Okimura

Ishida

Okamoto

Characterization of a cartilage-derived 66-kDa protein (RGD-CAP/beta ig-h3) that binds to collagen

Biochim. Biophys. Acta19971355303314

10.1016/S0167-4889(96)00147-4

9061001

Gibson

M.A.

Kumaratilake

J.S.

Cleary

E.G.

Immunohistochemical and ultrastructural localization of MP78/70 (betaig-h3) in extracellular matrix of developing and mature bovine tissues

J. Histochem. Cytochem19974516831696

10.1177/002215549704501212

9389772

Liu

Cheng

Lin

Hao

Zhang

Mitchel

R.E.

Sun

Zhao

Gao

Cai

MiR-21 plays an important role in radiation induced carcinogenesis in BALB/c mice by directly targeting the tumor suppressor gene Big-h3

Int. J. Biol. Sci20117347363

21494432

Sasaki

Kobayashi

Nakashima

Moriyama

Yukiue

Kaji

Kiriyama

Fukai

Yamakawa

Fujii

Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer

Jpn. J. Clin. Oncol2002328589

10.1093/jjco/hyf021

11956302

Rawe

I.M.

Zhan

Burrows

Bennett

Cintron

Beta-ig. Molecular cloning and in situ hybridization in corneal tissues

Invest. Ophthalmol. Vis. Sci199738893900

9112985

Gibson

M.A.

Kumaratilake

J.S.

Cleary

E.G.

The protein components of the 12-nanometer microfibrils of elastic and nonelastic tissues

J. Biol. Chem198926445904598

2647740

Schorderet

D.F.

Menasche

Morand

Bonnel

Buchillier

Marchant

Auderset

Bonny

Abitbol

Munier

F.L.

Genomic characterization and embryonic expression of the mouse Bigh3 (Tgfbi) gene

Biochem. Biophys. Res. Commun2000274267274

10.1006/bbrc.2000.3116

10913330

LeBaron

R.G.

Bezverkov

K.I.

Zimber

M.P.

Pavelec

Skonier

Purchio

A.F.

Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro

J. Invest. Dermatol1995104844849

10.1111/1523-1747.ep12607024

7738366

Kim

J.E.

Kim

S.J.

Lee

B.H.

Park

R.W.

Kim

K.S.

Kim

I.S.

Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3

J. Biol. Chem20002753090730915

10.1074/jbc.M002752200

10906123

Thapa

Lee

B.H.

Kim

I.S.

TGFBIp/betaig-h3 protein: A versatile matrix molecule induced by TGF-beta

Int. J. Biochem. Cell Biol20073921832194

10.1016/j.biocel.2007.06.004

17659994

Uekita

Kim

Y.J.

Yamanouchi

Tojo

Tachi

Dynamics of betaig-h3 mRNA expression during pregnancy in the uterus and the placenta of the mouse: A possible regulatory factor for trophoblastic invasion

J. Reprod. Dev200349243252

10.1262/jrd.49.243

14967934

Carson

D.D.

Lagow

Thathiah

Al-Shami

Farach-Carson

M.C.

Vernon

Yuan

Fritz

M.A.

Lessey

Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening

Mol. Hum. Reprod20028871879

10.1093/molehr/8.9.871

12200466

Gratchev

Guillot

Hakiy

Politz

Orfanos

C.E.

Schledzewski

Goerdt

Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3

Scand. J. Immunol200153386392

10.1046/j.1365-3083.2001.00885.x

11285119

Yun

S.J.

Kim

M.O.

Kim

S.O.

Park

Kwon

Y.K.

Kim

I.S.

Lee

E.H.

Induction of TGF-beta-inducible gene-h3 (betaig-h3) by TGF-beta1 in astrocytes: Implications for astrocyte response to brain injury

Brain Res. Mol. Brain Res20021075764

10.1016/S0169-328X(02)00447-3

12414124

Dokmanovic

Chang

B.D.

Fang

Roninson

I.B.

Retinoid-induced growth arrest of breast carcinoma cells involves co-activation of multiple growth-inhibitory genes

Cancer Biol. Ther200212427

12170760

Nam

E.J.

K.H.

You

D.W.

Cho

J.H.

Seo

J.S.

Han

S.W.

Park

J.Y.

Kim

S.I.

Kyung

H.S.

Kim

I.S.

Up-regulated transforming growth factor beta-inducible gene h3 in rheumatoid arthritis mediates adhesion and migration of synoviocytes through αvβ3 integrin: Regulation by cytokines

Arthritis Rheum20065427342744

10.1002/art.22076

16947382

Lee

S.H.

Kim

E.J.

Suk

Kim

I.S.

Lee

W.H.

TL1A induces the expression of TGF-beta-inducible gene h3 (βig-h3) through PKC, PI3K, and ERK in THP-1 cells

Cell. Immunol20102666166

10.1016/j.cellimm.2010.08.013

20863486

Shin

S.H.

Kim

Heo

S.C.

Kwon

Y.W.

Kim

Y.M.

Kim

I.S.

Lee

T.G.

Kim

J.H.

Proteomic identification of betaig-h3 as a lysophosphatidic acid-induced secreted protein of human mesenchymal stem cells: Paracrine activation of A549 lung adenocarcinoma cells by betaig-h3

Mol. Cell. Proteomics201211

10.1074/mcp.M111.012385

Lee

B.H.

Bae

J.S.

Park

R.W.

Kim

J.E.

Park

J.Y.

Kim

I.S.

Betaig-h3 triggers signaling pathways mediating adhesion and migration of vascular smooth muscle cells through αvβ5 integrin

Exp. Mol. Med200638153161

10.1038/emm.2006.19

16672769

O’Brien

E.R.

Bennett

K.L.

Garvin

M.R.

Zderic

T.W.

Hinohara

Simpson

J.B.

Kimura

Nobuyoshi

Mizgala

Purchio

Beta ig-h3, a transforming growth factor-beta-inducible gene, is overexpressed in atherosclerotic and restenotic human vascular lesions

Arterioscler. Thromb. Vasc. Biol199616576584

10.1161/01.ATV.16.4.576

8624780

Dieudonne

S.C.

Kerr

J.M.

Sommer

DeRubeis

A.R.

Kuznetsov

S.A.

Kim

I.S.

Gehron Robey

Young

M.F.

Differential display of human marrow stromal cells reveals unique mRNA expression patterns in response to dexamethasone

J. Cell. Biochem199976231243

10618640

Monticone

Liu

Tonachini

Mastrogiacomo

Parodi

Quarto

Cancedda

Castagnola

Gene expression profile of human bone marrow stromal cells determined by restriction fragment differential display analysis

J. Cell. Biochem200492733744

10.1002/jcb.20120

15211571

Thapa

Kang

K.B.

Kim

I.S.

Beta ig-h3 mediates osteoblast adhesion and inhibits differentiation

Bone200536232242

10.1016/j.bone.2004.08.007

15780949

Billings

P.C.

Whitbeck

J.C.

Adams

C.S.

Abrams

W.R.

Cohen

A.J.

Engelsberg

B.N.

Howard

P.S.

Rosenbloom

The transforming growth factor-beta-inducible matrix protein (beta)ig-h3 interacts with fibronectin

J. Biol. Chem20022772800328009

10.1074/jbc.M106837200

12034705

Hanssen

Reinboth

Gibson

M.A.

Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils

J. Biol. Chem20032782433424341

10.1074/jbc.M303455200

12719415

Reinboth

Thomas

Hanssen

Gibson

M.A.

Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules

J. Biol. Chem200628178167824

10.1074/jbc.M511316200

16434404

Kim

J.E.

Jeong

H.W.

Nam

J.O.

Lee

B.H.

Choi

J.Y.

Park

R.W.

Park

J.Y.

Kim

I.S.

Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the αvβ5 integrin

J. Biol. Chem20022774615946165

10.1074/jbc.M207055200

12270930

Ohno

Noshiro

Makihira

Kawamoto

Shen

Yan

Kawashima-Ohya

Fujimoto

Tanne

Kato

RGD-CAP (βig-h3) enhances the spreading of chondrocytes and fibroblasts via integrin α1β1

Biochim. Biophys. Acta19991451196205

10.1016/S0167-4889(99)00093-2

10446401

Bae

J.S.

Lee

S.H.

Kim

J.E.

Choi

J.Y.

Park

R.W.

Yong Park

Park

H.S.

Sohn

Y.S.

Lee

D.S.

Bae Lee

Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through α3β1 integrin

Biochem. Biophys. Res. Commun2002294940948

10.1016/S0006-291X(02)00576-4

12074567

Jeong

H.W.

Kim

I.S.

TGF-beta1 enhances betaig-h3-mediated keratinocyte cell migration through the α3β1 integrin and PI3K

J. Cell. Biochem200492770780

10.1002/jcb.20110

15211574

Kim

H.J.

Kim

I.S.

Transforming growth factor-beta-induced gene product, as a novel ligand of integrin αMβ2, promotes monocytes adhesion, migration and chemotaxis

Int. J. Biochem. Cell Biol2008409911004

10.1016/j.biocel.2007.11.001

18083624

Park

S.J.

Park

Ahn

H.C.

Kim

I.S.

Lee

B.J.

Conformational resemblance between the structures of integrin-activating pentapetides derived from betaig-h3 and RGD peptide analogues in a membrane environment

Peptides200425199205

10.1016/j.peptides.2003.12.002

15063001

Nam

J.O.

Kim

J.E.

Jeong

H.W.

Lee

S.J.

Lee

B.H.

Choi

J.Y.

Park

R.W.

Park

J.Y.

Kim

I.S.

Identification of the αvβ3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect

J. Biol. Chem20032782590225909

10.1074/jbc.M300358200

12704192

Lim

S.W.

Choi

B.S.

Lee

S.H.

Cha

J.H.

Kim

I.S.

Kim

Yang

C.W.

Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy

Am. J. Nephrol200525611620

10.1159/000089905

16308546

Lee

S.H.

Bae

J.S.

Park

S.H.

Lee

B.H.

Park

R.W.

Choi

J.Y.

Park

J.Y.

S.W.

Kim

Y.L.

Kwon

T.H.

Expression of TGF-beta-induced matrix protein betaig-h3 is up-regulated in the diabetic rat kidney and human proximal tubular epithelial cells treated with high glucose

Kidney Int20036410121021

10.1046/j.1523-1755.2003.00158.x

12911551

Cha

D.R.

Kim

I.S.

Kang

Y.S.

Han

S.Y.

Han

K.H.

Shin

Y.H.

Kim

N.H.

Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus

Diabet. Med2005221420

15610151

S.W.

Kim

H.J.

Bae

J.S.

Jeong

G.H.

Chung

S.C.

Kim

J.G.

Park

S.H.

Kim

Y.L.

Kam

Kim

I.S.

Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy

Diabetes Res. Clin. Pract200465167173

10.1016/j.diabres.2004.01.007

15223229

Han

J.H.

S.W.

Lee

I.K.

Kim

B.W.

Kim

J.G.

High glucose-induced apoptosis in bovine retinal pericytes is associated with transforming growth factor beta and betaIG-H3: BetaIG-H3 induces apoptosis in retinal pericytes by releasing Arg-Gly-Asp peptides

Clin. Exp. Ophthalmol201038620628

10.1111/j.1442-9071.2010.02276.x

Wang

Zhao

Loyd

Groome

L.J.

Increased urinary excretion of nephrin, podocalyxin, and betaig-h3 in women with preeclampsia

Am. J. Physiol. Renal. Physiol2012302F1084F1089

10.1152/ajprenal.00597.2011

22301621

Hedegaard

C.J.

Thogersen

I.B.

Enghild

J.J.

Klintworth

G.K.

Moller-Pedersen

Transforming growth factor beta induced protein accumulation in granular corneal dystrophy type III (Reis-Bucklers dystrophy). Identification by mass spectrometry in 15 year old two-dimensional protein gels

Mol. Vis20039355359

12942051

Konishi

Yamada

Nakamura

Mashima

Immunohistology of kerato-epithelin in corneal stromal dystrophies associated with R124 mutations of the BIGH3 gene

Curr. Eye Res200021891896

10.1076/ceyr.21.5.891.5536

11262611

Korvatska

Munier

F.L.

Chaubert

Wang

M.X.

Mashima

Yamada

Uffer

Zografos

Schorderet

D.F.

On the role of kerato-epithelin in the pathogenesis of 5q31-linked corneal dystrophies

Invest. Ophthalmol. Vis. Sci19994022132219

10476785

Streeten

B.W.

Klintworth

G.K.

Eagle

R.C.

JrStrauss

J.A.

Bennett

Immunolocalization of beta ig-h3 protein in 5q31-linked corneal dystrophies and normal corneas

Arch. Ophthalmol.19991176775

10.1001/archopht.117.1.67

9930162

Kannabiran

Klintworth

G.K.

TGFBI gene mutations in corneal dystrophies

Hum. Mutat200627615625

10.1002/humu.20334

16683255

Shao

Berenguer

Borczuk

A.C.

Powell

C.A.

Hei

T.K.

Zhao

Epigenetic inactivation of Betaig-h3 gene in human cancer cells

Cancer Res20066645664573

10.1158/0008-5472.CAN-05-2130

16651406

Skonier

Bennett

Rothwell

Kosowski

Plowman

Wallace

Edelhoff

Disteche

Neubauer

Marquardt

Beta ig-h3: A transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice

DNA Cell Biol199413571584

10.1089/dna.1994.13.571

8024701

Kim

J.E.

Kim

S.J.

Jeong

H.W.

Lee

B.H.

Choi

J.Y.

Park

R.W.

Park

J.Y.

Kim

I.S.

RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis

Oncogene20032220452053

10.1038/sj.onc.1206269

12673209

Zhao

Y.L.

Piao

C.Q.

Hei

T.K.

Overexpression of Betaig-h3 gene downregulates integrin α5β1 and suppresses tumorigenicity in radiation-induced tumorigenic human bronchial epithelial cells

Br. J. Cancer20028619231928

10.1038/sj.bjc.6600304

12085188

Zhao

Y.L.

Piao

C.Q.

Hei

T.K.

Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells

Oncogene20022174717477

10.1038/sj.onc.1205891

12386809

Zhao

Shao

Piao

C.Q.

Berenguer

Hei

T.K.

Down-regulation of Betaig-h3 gene is involved in the tumorigenesis in human bronchial epithelial cells induced by heavy-ion radiation

Radiat. Res2004162655659

10.1667/RR3270

15548115

Zhao

El-Gabry

Hei

T.K.

Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells

Mol. Carcinog2006458492

10.1002/mc.20167

16329146

Wen

Partridge

M.A.

Hong

Liao

Cheng

S.K.

Zhao

Calaf

G.M.

Liu

Zhou

TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells

Cancer Lett20113082332

10.1016/j.canlet.2011.04.010

21561707

Wen

Hong

Liao

Cheng

S.K.

Calaf

G.M.

Partridge

M.A.

Tong

Transforming growth factor-beta-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway

Int. J. Oncol20113910011009

21701776

Becker

Volland

Noskova

Schramm

Schweigerer

L.L.

Wilting

Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: A mechanism to inhibit invasion

Int. J. Oncol200832235240

18097563

Zamilpa

Rupaimoole

Phelix

C.F.

Somaraki-Cormier

Haskins

Asmis

Lebaron

R.G.

C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells

Matrix Biol200928347357

10.1016/j.matbio.2009.05.004

19505574

Zhang

Wen

Shao

Wang

Lin

Fang

Balajee

A.S.

Bhagat

Hei

T.K.

Zhao

TGFBI deficiency predisposes mice to spontaneous tumor development

Cancer Res2009693744

19117985

Kang

Dong

S.M.

Park

N.H.

Frequent promoter hypermethylation of TGFBI in epithelial ovarian cancer

Gynecol. Oncol20101185863

10.1016/j.ygyno.2010.03.025

20421128

Wang

Zhang

Yao

Wang

Dai

Yang

TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer

J. Exp. Clin. Cancer Res201231

10.1186/1756-9966-31-6

Ween

M.P.

Lokman

N.A.

Hoffmann

Rodgers

R.J.

Ricciardelli

Oehler

M.K.

Transforming growth factor-beta-induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells

Int. J. Cancer201112815701584

10.1002/ijc.25494

20521251

Calaf

G.M.

Echiburu-Chau

Zhao

Y.L.

Hei

T.K.

BigH3 protein expression as a marker for breast cancer

Int. J. Mol. Med200821561568

18425347

Ivanov

S.V.

Ivanova

A.V.

Salnikow

Timofeeva

Subramaniam

Lerman

M.I.

Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors

Biochem. Biophys. Res. Commun2008370536540

10.1016/j.bbrc.2008.03.066

18359287

Yamanaka

Kimura

Kagata

Kondoh

Asano

Yamamoto

Hayakawa

BIGH3 is overexpressed in clear cell renal cell carcinoma

Oncol. Rep200819865874

18357369

Hourihan

R.N.

O’Sullivan

G.C.

Morgan

J.G.

Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues

Anticancer Res200323161165

12680208

Kitahara

Furukawa

Tanaka

Kihara

Ono

Yanagawa

Nita

M.E.

Takagi

Nakamura

Tsunoda

Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia

Cancer Res20016135443549

11325815

Golembieski

W.A.

Rempel

S.A.

cDNA array analysis of SPARC-modulated changes in glioma gene expression

J. Neurooncol200260213226

10.1023/A:1021167211131

12510773

Schneider

Kleeff

Berberat

P.O.

Zhu

Korc

Friess

Buchler

M.W.

Induction and expression of betaig-h3 in pancreatic cancer cells

Biochim. Biophys. Acta2002158816

10.1016/S0925-4439(02)00052-2

12379307

Aitkenhead

Wang

S.J.

Nakatsu

M.N.

Mestas

Heard

Hughes

C.C.

Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, (beta)ig-h3, and NrCAM

Microvasc. Res200263159171

10.1006/mvre.2001.2380

11866539

Zajchowski

D.A.

Bartholdi

M.F.

Gong

Webster

Liu

H.L.

Munishkin

Beauheim

Harvey

Ethier

S.P.

Johnson

P.H.

Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells

Cancer Res20016151685178

11431356

Rong

Radiloff

D.R.

Datto

M.B.

Centeno

Bao

Cheng

A.W.

Lin

Jiang

Yeatman

T.J.

Extracellular matrix protein βig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation

Genes Dev200822308321

10.1101/gad.1632008

18245446

Kim

M.O.

Yun

S.J.

Kim

I.S.

Sohn

Lee

E.H.

Transforming growth factor-beta-inducible gene-h3 (βig-h3) promotes cell adhesion of human astrocytoma cells in vitro: Implication of α6β4 integrin

Neurosci. Lett20033369396

10.1016/S0304-3940(02)01260-0

12499048

Tang

Zhou

H.W.

Jiang

J.L.

Yang

X.M.

Zhang

H.X.

Chen

Z.N.

Guo

W.P.

BetaIg-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells

Exp. Biol. Med2007232344352 74

Tang

Y.M.

Zhao

Jiang

J.L.

Chen

Z.N.

Betaig-h3 interacts with α3β1 integrin to promote adhesion and migration of human hepatoma cells

Exp. Biol. Med20092343539

10.3181/0806-RM-187

Irigoyen

Anso

Salvo

de las Herrerias

J.D.

Martinez-Irujo

J.J.

Rouzaut

TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions

Cell. Mol. Life Sci20086522442255

10.1007/s00018-008-8071-9

18560760

Nummela

Lammi

Soikkeli

Saksela

Laakkonen

Holtta

Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells

Am. J. Pathol201218016631674

10.1016/j.ajpath.2011.12.035

22326753

Guo

Y.S.

Tang

Chen

Huang

Cui

H.Y.

Zhang

Wang

S.J.

Chen

Z.N.

Jiang

J.L.

Betaig-h3 regulates store-operated Ca2+ entry and promotes the invasion of human hepatocellular carcinoma cells

Cell Biol. Int201135811817

10.1042/CBI20100916

21395558

Y.C.

Lam

K.Y.

Law

Wong

Srivastava

Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: Overexpression of oncogene MET correlates with tumor differentiation in ESCC

Clin. Cancer Res2001735193525

11705871

Wong

F.H.

Huang

C.Y.

L.J.

Y.C.

Lin

Y.S.

Hsia

J.Y.

Tsai

H.T.

Lee

S.A.

Lin

C.H.

Tzeng

C.H.

Combination of microarray profiling and protein-protein interaction databases delineates the minimal discriminators as a metastasis network for esophageal squamous cell carcinoma

Int. J. Oncol200934117128

19082484

Turtoi

Musmeci

Wang

Dumont

Somja

Bevilacqua

de Pauw

Delvenne

Castronovo

Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma

J. Proteome Res20111043024313

10.1021/pr200527z

21755970

Tomioka

Morita

Hasegawa

Omura

Gene expression analysis by cDNA microarray in oral squamous cell carcinoma

J. Oral Pathol. Med200635206211

10.1111/j.1600-0714.2006.00410.x

16519767

Lin

Madan

Yoon

J.G.

Fang

Yan

Kim

T.K.

Hwang

Hood

Foltz

Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma

PLoS One20105e10210

10.1371/journal.pone.0010210

20419098

Cui

S.M.

Duan

Y.H.

Heng

L.J.

Wang

Gao

G.D.

Human U87 astrocytoma cell invasion induced by interaction of βig-h3 with integrin α5β1 involves calpain-2

PLoS One20127e37297

10.1371/journal.pone.0037297

22629380

Buckhaults

Rago

St Croix

Romans

K.E.

Saha

Zhang

Vogelstein

Kinzler

K.W.

Secreted and cell surface genes expressed in benign and malignant colorectal tumors

Cancer Res20016169967001

11585723

Ohno

Izumi

Tachibana

Kawamura

Yoshioka

Aoyagi

Ohori

Namiki

Sakamoto

Nakagami

Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines

Oncol. Rep200820501509

18695898

Ahmed

A.A.

Mills

A.D.

Ibrahim

A.E.

Temple

Blenkiron

Vias

Massie

C.E.

Iyer

N.G.

McGeoch

Crawford

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel

Cancer Cell200712514527

10.1016/j.ccr.2007.11.014

18068629

Tumbarello

D.A.

Temple

Brenton

J.D.

Beta3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells

Mol. Cancer201211

10.1186/1476-4598-11-36

Clout

N.J.

Hohenester

A model of FAS1 domain 4 of the corneal protein beta(ig)-h3 gives a clearer view on corneal dystrophies

Mol. Vis20039440448

14502125

Gardner

M.J.

Jones

L.M.

Catterall

J.B.

Turner

G.A.

Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis

Cancer Lett199591229234

10.1016/0304-3835(95)03743-G

7539337

Witz

C.A.

Takahashi

Montoya-Rodriguez

I.A.

Cho

Schenken

R.S.

Expression of the α2β1 and α3β1 integrins at the surface of mesothelial cells: A potential attachment site of endometrial cells

Fertil. Steril200074579584

10.1016/S0015-0282(00)00701-9

10973658

Heyman

Kellouche

Fernandes

Dutoit

Poulain

Carreiras

Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro

Tumour Biol200829231244

10.1159/000152941

18781095

Cannistra

S.A.

Abu-Jawdeh

Niloff

Strobel

Swanson

Andersen

Ottensmeier

CD44 variant expression is a common feature of epithelial ovarian cancer: Lack of association with standard prognostic factors

J. Clin. Oncol19951319121921

7543560

Strobel

Cannistra

S.A.

Beta1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro

Gynecol. Oncol199973362367

10.1006/gyno.1999.5388

10366461

Park

Y.H.

Ryu

H.S.

Choi

D.S.

Chang

K.H.

Park

D.W.

Min

C.K.

Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture

Int. J. Gynecol. Cancer2003135360

10.1046/j.1525-1438.2003.13033.x

12631221

Walker

MacLeod

Williams

A.R.

Cameron

D.A.

Smyth

J.F.

Langdon

S.P.

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

Gynecol. Oncol2007106461468

10.1016/j.ygyno.2007.05.009

17624412

Irigoyen

Pajares

M.J.

Agorreta

Ponz-Sarvise

Salvo

Lozano

M.D.

Pio

Gil-Bazo

Rouzaut

TGFBI expression is associated with a better response to chemotherapy in NSCLC

Mol. Cancer20109

10.1186/1476-4598-9-130

Figures and Tables Figure 1

Schematic diagram of Transforming growth factor-beta-induced protein (βig-H3) protein structure. Secretory signal (SP) in the N-terminal cysteine rich domain (CRD), and four fasciclin-1 domains (FAS1 1–4). Position of several known integrin binding motifs, including NKDIL, YH18, EPDIM and Arg-Gly-Asp (RGD), are indicated.

Figure 2

H & E and βig-H3 immunostaining of ovarian tissues. (a) Normal ovary surface epithelium; (b) Benign serous cystadenoma; (c) Serous ovarian carcinoma. Scale bar = 100 μm for all images. Immunostaining with polyclonal rabbit βig-H3 antibody (Santa Cruz Biotechnology) as described in [61].

Table 1

Studies reporting a tumor suppressor role for βig-H3.

Cell Type	Observation	References
CHO cells	βig-H3 inhibits cell attachment in vitro and suppresses the growth of CHO tumor cells in nude mice	[48]
CHO cells	RGD peptides released from βig-H3 mediate apoptosis of CHO tumor cells	[49]
HeLa cells	RGD peptides released from βig-H3 mediate apoptosis of HeLa tumor cells	[49]
Bronchial epithelial cells	βig-H3 overexpression suppresses tumorigenicity in radiation-induced tumorigenic human bronchial epithelial cells	[50]
	Loss of βig-H3 expression is associated with the tumorigenic phenotype in asbestos-treated bronchial epithelial cells	[51]
	βig-H3 gene down-regulation is involved in heavy-ion radiation-induced tumorigenesis of human bronchial epithelial cells	[52]
Lung adenocarcinoma	Loss of βig-H3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells	[53]
	Promoter methylation contributes to promoter silencing of the βig-H3 gene in human lung cancer cells	[47]
	βig-H3 is down-regulated in radiation-induced thymic lymphoma model in BALB/c mice	[5]
	βig-H3 overexpression in H522 lung carcinoma cells reduces motility in vitro and metastasis in vivo	[54]
	RGD βig-H3 peptides mediate apoptosis of H1299 lung carcinoma cells	[49]
Mesothelioma cell lines	βig-H3 knockdown increases proliferation and anchorage independent growth of mesothelioma cell lines	[55]
Breast carcinoma	βig-H3 protein expression is reduced in in situ ductal carcinoma and breast carcinoma tissues, compared to benign tissues	[54]
Breast carcinoma	βig-H3 overexpression in MCF-7 cells reduces motility in vitro and metastasis in vivo	[54]
Neuroblastoma	βig-H3 significantly reduces proliferation and invasion of neuroblastoma cell in vitro and in vivo	[2,56]
Osteosarcoma	C-terminal fragment of βig-H3 is required for apoptosis in human osteosarcoma cells	[57]
Hepatoma	RGD βig-H3 peptides mediate apoptosis of Hep3B hepatoma cells	[47]
Knockout mice	βig-H3 knockout mice are prone to spontaneous tumors	[58]
Ovarian carcinoma	βig-H3 silencing and promoter hypermethylation is a frequent occurrence in ovarian cancer cell lines and ovarian cancer tissues	[59,60]
	βig-H3 is down-regulated in serous ovarian carcinoma and borderline serous ovarian tumors	[61]
	βig-H3 induces apotosis in serous ovarian carcinoma cell lines	[61]

Table 2

Studies reporting a tumor-promoting role for βig-H3.

Cell type	Observation	References
Lung adenocarcinoma	βig-H3 is overexpressed in lung cancer	[6]
Lung adenocarcinoma	Recombinant βig-H3 stimulates proliferation and cell adhesion of A549 cells	[20]
Oesophageal adenocarcinoma	βig-H3 is up-regulated in oesophageal adenocarcinoma and esophageal squamous cell carcinoma tissues and cell lines tissue	[65,78,79]
Pancreatic cancer	βig-H3 expression is increased in pancreatic cancer cell lines and tissues	[68,80]
Oral squamous cell carcinoma	βig-H3 expression is increased in oral squamous cell carcinoma tissues	[81]
Brain tumors	βig-H3 promotes cell adhesion of human astrocytoma cells in vitro via interactions with α6β4 integrin	[72]
	βig-H3 expression is elevated in glioblastoma multiforme tissues	[82]
	Knockdown of βig-H3 inhibits glioma cell invasion and MMP secretion	[83]
Hepatocellular carcinoma	βig-H3 knockdown reduced invasion of 7721 cells	[73]
Hepatocellular carcinoma	βig-H3 interacts with α3β1 integrin to promote adhesion and invasion of 7721 cells	[74]
Colon carcinoma	βig-H3 expression is elevated in human colon carcinoma tissues	[64,84]
Colon carcinoma	Overexpression of βig-H3 promotes extravasation and enhances metastasis of colon cancer cells	[71]
Renal cell carcinoma	βig-H3 is up-regulated in clear cell renal carcinoma	[63,64]
Renal cell carcinoma	βig-H3 expression is increased in metastastic renal cell carcinoma	[85]
Ovarian carcinoma	βig-H3 suppression leads to a chemoresistant phenotype	[86,87]
	Recombinant βig-H3 promotes motility and invasion of OVCAR-5 and SKOV3 cells	[61]
	Recombinant βig-H3 promotes adhesion of OVCAR-3, OVCAR-5 and SKOV3 cells	[61]